Deutsche Bank analyst Emmanuel Papadakis lowered the firm’s price target on Sanofi (SNY) to EUR 105 from EUR 110 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi Targets Pfizer’s Pneumococcal Stronghold With New Phase 3 Infant Vaccine Trial
- Trump Trade: White House releases details on ‘Great Healthcare Plan’
- Drugmakers concerned about legal risk with FDA review program, Reuters reports
- Sanofi Wins First EU Disease‑Modifying Approval for Type 1 Diabetes Drug Teizeild
- Sanofi downgraded to Neutral from Buy at UBS